One is an integrase inhibitor, a new class of antivirals, for HIV.

FORBES: Gilead's Half-Empty Pipeline

Merck did fine here, with many years as the only maker of an integrase inhibitor, but it does seem the companies following in its wake may have an easier time.

FORBES: An Innovator's Dilemma For Merck AIDS Drug